Novateor Research Laboratories Ltd
Novateor Research Laboratories Ltd (NOVATEOR) last traded at ₹32.8, a market capitalisation of ₹19.9 crore, on a P/E of 199. Over the past 52 weeks the stock has ranged between ₹20.1 and ₹34.5. Novateor Research Laboratories Ltd last reported results for the quarter ended Mar 2026, with sales of ₹1.36 crore and net profit of ₹0.12 crore. Figures are as of 25 Aug 2026 and are not real time.
Novateor Research Laboratories Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Novateor Research Laboratories Ltd quarterly results
In the quarter ended Mar 2026, sales were ₹1.36 cr, down 31.3% from ₹1.98 cr a year earlier. Net profit was ₹0.12 cr, up 140.0% year on year.
| ₹ crore | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0.82 | 0.44 | 0.36 | 0.85 | 0.79 | 1.98 | 2.47 | 1.36 |
| Expenses | 1.01 | 0.58 | 0.53 | 1 | 0.9 | 2 | 2.59 | 1.35 |
| Operating profit | -0.19 | -0.14 | -0.17 | -0.15 | -0.11 | -0.02 | -0.12 | 0.01 |
| OPM % | -23.17% | -31.82% | -47.22% | -17.65% | -13.92% | -1.01% | -4.86% | 0.74% |
| Other income | 0.24 | 0.25 | 0.24 | 0.24 | 0.24 | 0.24 | 0.25 | 0.24 |
| Interest | 0 | 0.03 | 0.02 | 0.01 | 0.02 | 0.05 | 0.05 | 0.04 |
| Depreciation | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.1 | 0.09 | 0.09 |
| Profit before tax | 0.01 | 0.04 | 0.01 | 0.04 | 0.05 | 0.07 | -0.01 | 0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 20.00% | 28.57% | 100.00% | 8.33% |
| Net profit | 0.01 | 0.03 | 0.01 | 0.04 | 0.03 | 0.05 | -0.02 | 0.12 |
| EPS (₹) | 0.02 | 0.06 | 0.02 | 0.08 | 0.06 | 0.10 | -0.03 | 0.20 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Novateor Research Laboratories Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 0.19 | 0.74 | 1.26 | 1.21 | 2.78 | 3.83 |
| Operating profit | -0.33 | -0.18 | -0.34 | -0.33 | -0.14 | -0.1 |
| OPM % | -173.68% | -24.32% | -26.98% | -27.27% | -5.04% | -2.61% |
| Net profit | 0.01 | -0.23 | 0.04 | 0.03 | 0.08 | 0.1 |
| EPS (₹) | 0.02 | -0.48 | 0.08 | 0.06 | 0.17 | 0.17 |
TTM is the trailing twelve months to the most recent quarter.
Novateor Research Laboratories Ltd growth and returns
- 10 Years
- 44%
- 5 Years
- 82%
- 3 Years
- 45%
- TTM
- 38%
- 10 Years
- %
- 5 Years
- 58%
- 3 Years
- 36%
- TTM
- 25%
- 10 Years
- %
- 5 Years
- 40%
- 3 Years
- 5%
- 1 Year
- -17%
- 10 Years
- 1%
- 5 Years
- 1%
- 3 Years
- 1%
- Last Year
- 1%
Novateor Research Laboratories Ltd shareholding pattern
Promoters held 50.75% at Mar 2026, down from 60.87% at Sep 2024.
| % held | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | May 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 60.87% | 60.87% | 60.87% | 60.87% | 60.87% | 51.60% | 50.90% | 50.75% |
| Public | 39.13% | 39.13% | 39.13% | 39.12% | 39.13% | 48.40% | 49.09% | 49.24% |
| No. of shareholders | 113 | 118 | 122 | 160 | 142 | 164 | 172 | 172 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Novateor Research Laboratories Ltd corporate filings
- The company has entered into Marketer and Manufacturing Agreement with Smart Laboratories Private Limited and received Purchase order from them for 10000 units Advance Teeth Whitening Serum ....Company Updatemedium impact
Cruxal's analysis: Novateor Research Laboratories Limited has entered into a Marketer and Manufacturer…
Read the full analysis - Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulation, 2018 for the quarter ended June 30, 2026Company Updatelow impact
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Novateor Research Laboratories Ltd
Cruxal reads every Novateor Research Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.